Population balance modelling captures host cell protein dynamics in CHO cell cultures

Sakhr Alhuthali*, Cleo Kontoravdi
Department of Chemical Engineering, Imperial College London, London, United Kingdom

* s.alhuthali15@imperial.ac.uk

Abstract

Monoclonal antibodies (mAbs) have been extensively studied for their wide therapeutic and research applications. Increases in mAb titre has been achieved mainly by cell culture media/feed improvement and cell line engineering to increase cell density and specific mAb productivity. However, this improvement has shifted the bottleneck to downstream purification steps. The higher accumulation of the main cell-derived impurities, host cell proteins (HCPs), in the supernatant can negatively affect product integrity and immunogenicity in addition to increasing the cost of capture and polishing steps. Mathematical modelling of bioprocess dynamics is a valuable tool to improve industrial production at fast rate and low cost. Herein, a single stage volume-based population balance model (PBM) has been built to capture Chinese hamster ovary (CHO) cell behaviour in fed-batch bioreactors. Using cell volume as the internal variable, the model captures the dynamics of mAb and HCP accumulation extracellularly under physiological and mild hypothermic culture conditions. Model-based analysis and orthogonal measurements of lactate dehydrogenase activity and double-stranded DNA concentration in the supernatant show that a significant proportion of HCPs found in the extracellular matrix is secreted by viable cells. The PBM then served as a platform for generating operating strategies that optimise antibody titre and increase cost-efficiency while minimising impurity levels.

1 Introduction

Monoclonal antibodies (mAbs) and derived products such as antibody-drug conjugates, Fc-fusion proteins and antibody fragments, are widely used in many diagnostic and therapeutic applications [1]. Chinese hamster ovary (CHO) cells are the most commonly used host for industrial mAb production, accounting for 84% of currently approved products [2]. mAb yield increased from 50 mg/L in 1986 to 3–10 g/L in 2010s as a result of a variety of genetic and process optimisation techniques that led to increased cell density and specific mAb productivity [3–5]. However, achieving higher cell densities has also led to the accumulation of cell-derived impurities over culture duration, posing challenges for downstream separation [6,7].

Host cell proteins (HCPs) are a heterogeneous mixture of proteins secreted by viable cells and intracellular proteins released from dead and lysed cells toward the end of the culture [7].
In their majority, HCPs are removed in the downstream step of protein A affinity chromatography, however, some persist after this unit operation and their removal requires further chromatographic separation steps [8]. Certain HCPs have proteolytic activity and can cause product fragmentation (and subsequent aggregation) while others can lead to immunogenic responses in patients if not fully removed [6]. The concentration and properties of residual HCPs present in process intermediates and the drug product are therefore of significant interest [9,10].

HCP concentration typically increases with cell culture duration and correlates with the number of dead cells, even though HCPs are also known to be secreted by viable cells [6,11]. Although the goal of upstream operations has typically been to increase yield, which often involves improved feeding regimes to increase culture longevity, this is not necessarily beneficial from the point of view of downstream processing effort and cost. The ability to quantify the trade-off between increased yield and raised purification effort could therefore support decision-making during process development, such as optimal harvest time. Including the level of impurities in upstream process models paves the way for multi-objective optimisation of both upstream processing steps and the entire flowsheet to reduce the process development and manufacturing cost of therapeutic proteins and increase overall process efficiency.

To this end, modelling of cell culture dynamics has been a valuable tool in enhancing our understanding of cellular responses to process changes [12,13]. We propose that modelling can be used to quantify this trade-off between gains in upstream operations and burden on downstream purification by predicting the accumulation of dead cells, which is responsible for HCP release extracellularly and is often underestimated by trypan blue dye exclusion methods [14]. However, such a model would also need to account for HCP secretion by viable cells and, by extension, accurately represent cell volume, which is correlated to the total protein content per cell [15].

Population balance modelling (PBM) has been developed to model different complex dynamic systems that are characterised by distributions [16–22]. These models have a time-dependent probability density function, which represents a state variable such as cell volume or DNA content. The distribution changes with time as a result of growth, death and birth mechanisms [18,23,24]. PBM has been used extensively to describe cell population dynamics in a variety of bioreactor systems and across different microorganisms [25–28]. However, the application of PBM with a single internal variable model is limited to balanced growth conditions [29,30], under which it is reasonable to assume that cell division follows a fixed normal distribution of cell size [31]. This is not applicable to the fed-batch culture of CHO cells, in which cell volume increases significantly in late-stage culture due to an increase in culture osmolality [32–34]. Mantzaris et al. and Zhu et al. were among the first to model the evolution of cell volume distribution in yeast, which led to the model being split into two different stages, smaller cells with high proliferation rate and larger ones with high recombinant protein productivity [28,30].

These papers along with others [29,35,36] emphasise the importance of uncoupling cell growth in size from cell density when growth medium nutrient and metabolite concentration change. This modelling approach is called multi-stage PBM, in which the number of model equations increases with the number of population balance stages considered. Given previous observations on the link between cell volume, growth rate and culture osmolality [34,37–39], we propose a simpler approach for modelling the effect of osmolality. Specifically, we propose the inclusion of culture osmolality in the growth rate equation and division function to capture (a) growth rate reduction and (b) cell volume increase under hyperosmolar culture conditions.

We have previously shown that CHO cells divide at a lower rate and larger cell volume as extracellular osmolality increases (i.e., 400 mOsm kg\(^{-1}\)) before cell division ceases at higher
osmolality values (~500 mOsm kg⁻¹) [34]. This cell volume increase is observed with every new generation of cells and can be considered in the division function of the PBM by adjusting the mean volume and standard deviation at which cells divide. These values are typically taken from literature, but can be updated based on experimental data on cell volume distribution for the cell line and process conditions at hand [36,40]. It is also possible for the division mean and standard deviation to be formulated as a function of culture osmolality such that an increase in CHO cell volume leads to division only if extracellular conditions (i.e., substrate and metabolite concentrations) are conducive to cell proliferation. Hence, we present a single-stage volume-based population balance model formulation for mAb-producing CHO cell cultures. The PBM captures cell density and volume growth dynamics, mAb production, as well as the accumulation of HCPs extracellularly as a measure of downstream burden under two culture temperatures: 36.5°C and 32°C. The model is then used to understand the mechanisms by which HCPs accumulate in the extracellular matrix and to compare optimal culture conditions for different objectives. We anticipate that the model can guide decision-making with respect to optimal harvest time to maintain high product recovery and HCP impurity clearance and, with further data on HCP stability, can refine our understanding of their origin.

2 Materials and methods

2.1 Model formulation

The main equation of PBM for a single compartment and a single internal variable, cell volume in this case, is:

\[ \text{Accumulation} + \text{Growth} + \text{Division} + \text{Death} + \text{Dilution} = \text{Birth} \]  \hspace{1cm} (1)

The mathematical representation of these terms is given by Eq (2).

\[
\begin{align*}
\frac{\partial n(v,t)}{\partial t} + \frac{\partial}{\partial v} \left( g(v,s)n(v,t) \right) + \Gamma(v,s)n(v,t) + D(s)n(v,t) + \frac{F_{in}}{V} n(v,t) \\
&= 2 \int_{v_{min}}^{v_{max}} P(v',v) \Gamma(v',s)n(v',t) dv'
\end{align*}
\]  \hspace{1cm} (2)

\( n(v,t) \) is number of cells in million per unit volume of the continuous internal normalised phase (normalised cell volume) per unit volume of the discrete phase (L of culture) at time t. The integral of \( n(v,t) \) is called the 0th moment, which gives the number density of cells across all cell sizes [41]. The terms \( v' \) and \( v \) represent the volume of mother and daughter cells, respectively, with further details provided in section 2.1.3. The integration of cell volume in the model is important because metabolic flux across the membrane, biosynthetic capacity and nutrient exchange depend on cell size [42,43]. The nucleus, mitochondria, endoplasmic reticulum and gene expression scale with cell size in human and yeast cells [44–48].

2.1.1 Growth rate. Most of cell growth rate equations used in PBM [49–53] involve a distributed linear domain like the volume shown in Eq (3) below. The linear cell volume growth function for CHO cells was suggested by Anderson et al. similarly to studies in other microorganisms [54,55].

\[ g(v,s) = \mu_{max} f_{lim} f_{inh} v \]  \hspace{1cm} (3)

\[ f_{lim} = \frac{C_{as}}{C_{as} + K_{as}} \]  \hspace{1cm} (4)
The population growth rate $g(v, s)$ is in units of $h^{-1}$ due to the volume domain being normalised. The growth rate depends on substrate limitation (Eq (4)), metabolite inhibition (Eq (5)) and the normalised cell volume $v$. Asparagine is the main growth-limiting substrate and ammonia inhibits growth for this cell line (see Kyriakopoulos and Kontoravdi [56]). The $K_{\text{asn}}$ and $K_{\text{amm}}$ are the Monod and inhibition constants ($mM$), respectively. Lopez-Meza et al. linked growth to substrate concentration for wild-type and protein-producing CHO cells whereas Stamatakis et al. qualitative PBM assumed cell growth as a function of volume alone [57,58]. In Eq (5) for the growth inhibition function, $f_{\text{inh}}$, the effect of osmolality is accounted for in last term in accordance with literature and is further discussed in the osmolality section [34,38]. The constant $K_{\text{Osm}}$ in Eq (5) has a value of 256 mOsm kg$^{-1}$. Eq (5) is only valid for the given osmolality range. This is because our cell culture medium has initial osmolality value of 320 mOsm kg$^{-1}$ and osmolality above 500 will lead to inhibitory condition, $f_{\text{inh}}$ turns to zero at 565 which is well above the operating range. It is worth mentioning that the parameters involved in Eq (5) should be experimentally verified before implementation for different cell line or culture medium.

Linardos et al. reported the exponential relationship between the cell death rate and average cell age [59,60]. The death rate is an exponential function as shown in Eq (6) and positively correlated to the reduction in proliferation rate [59,61,62]. Eq (7) accounts for cell lysis rate of dead cells. The accumulation of lysed cells can be quantified by Eq (8).

$$f_{\text{inh}} = \frac{K_{\text{amm}}}{K_{\text{Osm}} + K_{\text{amm}}} \left(\frac{-Osm}{K_{\text{Osm}}} + 2.2\right) \quad 315\text{mOsm kg}^{-1} < Osm < 560\text{ mOsm kg}^{-1} \tag{5}$$

In Eq (6), $k_{d, \text{max}} (h^{-1})$ is the maximum death rate and $k_d (h^{-1})$ is another constant specific to the cell line which is the growth rate at which the death rate is at a maximum value. $k_i (h^{-1})$ in the Eq (7) is the cell lysis rate. $N_d (10^{6} \text{ cell L}^{-1})$ is the density of dead cells given in the same unit as viable cell density $N$ in Eq (9). The cell density ($10^{6} \text{ cell L}^{-1}$) can be found by integrating the distributions of viable cell population from the minimum to the maximum cell volume as shown in Eq (9). In this case, the minimum volume is zero and the maximum is unity. The boundary condition in Eq (10) signifies that there is not a cell which has volume of zero at any time.

$$D(s) = k_{d, \text{max}} e^{\left(-\frac{\text{inh} + \text{lim}}{k_d}\right)} \tag{6}$$

$$\frac{dN_d}{dt} = \int_{v_{\text{min}}}^{v_{\text{max}}} D(s)n(v, t)dv - k_i N_d \tag{7}$$

$$\frac{dN_i}{dt} = k_i N_d \tag{8}$$

$$N = \int_{v_{\text{min}}}^{v_{\text{max}}} n(v, t)dv \tag{9}$$

$$n_d(0, t) = 0 \tag{10}$$

The following two equations are the initial conditions for dead and lysed cells. Eq (13) is
used to calculate the average cell volume.

\[ N_d(v,0) = 0 \]  
\[ N_l(v,0) = 0 \]

\[ \bar{v} = \frac{\int_{v_{	ext{min}}}^{v_{	ext{max}}} v n(v,t) \, dv}{N} \]  

\( \bar{v} \) is the average cell volume which is normalised and the corresponding value in \( \mu m^3 \) can be obtained by multiplying the value by the maximum cell volume 6,044 \( \mu m^3 \), based on 22.6 \( \mu m \) maximum diameter. This maximum diameter is well above typically reported values to ensure that the entire cell population is within the distribution limits [32,34,63]. The initial distribution is based on 5,000–10,000 CHO cells and was derived from experimental data using MATLAB (Generalised Extreme Value) as shown in Eq (14).

\[ n_a(v,0) = \frac{1}{\sigma} \left[ 1 + e^{\left( \frac{v - \mu}{\sigma} \right)^2} \right] e^{-\left[ 1 + e^{(\frac{\bar{v}}{\sigma})} \right]^{\frac{1}{2}}} \]  

This type of dataset on cell diameter distribution can be obtained using common automated cell counters such as the NucleoCounter \textsuperscript{TM} NC-250 used herein. All the outliers in cell size, such as cell aggregates and fragments observed particularly in late days of culture were removed from the dataset. This is because it is known that the cells’ tendency to aggregate around a dead cell is higher at later stages of cell culture [64]. A careful treatment of cell volume data was required to eliminate the outliers as they might skew the cell size distribution beyond the generally reported CHO cell size [32,65]. The range was limited for diameters between 5 and 22 \( \mu m \) for viable cells based on our own data and previous observations [34,65]. However, the interval between 5 and 10 \( \mu m \) has almost no viable cells but should be added to prevent the fitted probability density function from starting at a value of almost zero volume.

### 2.1.2 Division function.

The division function reflects the increased probability of division as cell volume increases, as shown in Eq (15). The division probability positive correlation with volume or age within the cell cycle is explained in the literature [66,67]. It is a function of the substrate through the addition of the growth rate. It simply means that there is no division if there is no growth. However, there are many other formulae, including discrete discontinuous, that are used in the literature [35,68–71]. The \( v_c \) in Eq (15) is the mean of cell volume at division, which is positively correlated to osmolality based on our data. The cell division rate for a specific mean and across a range of standard deviation values is shown in S1 Fig.

\[ \Gamma(v,s) = \frac{2e^{-\left( \frac{v}{s} \right)^2} g(v,s)}{e^{\sqrt{\pi} \text{erf} c\left( \frac{v}{s} \right)}} \]  

\( \Gamma(v,s) \) is the cell division rate (\( h^{-1} \)). It is important at this stage to briefly revisit the history of the division function. The division function theoretically originated from Eakman et al. who stated that “there appears to be little conclusive evidence to support the assumption that the distribution of division mass deviates markedly from Gaussian. Therefore, it is assumed that the distribution of division mass around a division cell size mean is of a Gaussian type” [31]. This function relies on certain assumptions such as constant extracellular environment, homogeneous mixing and exponential cell growth [55]. While it is convincing to accept that the distribution at division as a Gaussian type based on experimental measurements, several studies attempted to determine at what size a cell divides and what is the full spectrum of extracellular and intracellular drivers affecting cell volume growth [72–74].
There are many factors that affect microbial and mammalian cell volume such as cell cycle position [75,76], cell culture conditions, [77], cell cycle arrest [77], glutamine depletion [78], and many others [79,80]. To the best of our knowledge, size-based PBM has never been utilised for fed-batch CHO cell culture. Most of the aforementioned PBMs for microbial batch cultures are qualitative and ignore the effect of culture osmolality. An update is therefore suggested herein to integrate the experimentally observed shift in cell volume distribution by updating the division function. Capturing the cell volume increase would lead to better estimation of HCP volumetric secretion from dead cells by more accurately reflecting the protein content per cell.

2.1.3 Partition function. The partition probability density function in Eq (16) is used to represent the asymmetric division phenomenon. [36,71]. The addition of this equation is important to capture self-similar distribution, which is the case for all cell culture system starting without imposed cell cycle arrest. This equation leads to the production of two daughter cells (i.e., \( v' \) and \( v - v' \) at time \( t + dt \)) with a total size equal to that of their mother cell. More details with regards to the derivation of this equation can be found in the literature [81].

\[
P(v, v') = \frac{1}{\beta(q, q)} \frac{1}{v} \left( \frac{v}{v'} \right)^{q-1} \left( 1 - \frac{v}{v'} \right)^{q-1}
\]  

(16)

2.1.4 Substrate and metabolite profile. The glucose and lactate profile have been coupled to capture the shift in lactate from production to consumption. Similarly, ammonia is produced from amino acid metabolism and degradation. For CHO cells and the GS-CHO cell line used herein, we can mainly attribute ammonia synthesis to asparagine and glutamine metabolism [82,83].

The following equations represent the mass balances of key amino acids, glucose, metabolites, impurities, and product. These simplified coupled equations and relationships can be found in the literature [32,82,84–86]. Asparagine is consumed at a rate given in Eq (17) with the yield \( Y_{asn} \) (mmol cell\(^{-1} \)). All \( Q \) terms (mmol cell\(^{-1} \) h\(^{-1} \)) in the equations below are specific consumption rates for the amino acids and glucose and production rates for the metabolites.

\[
Q_{asn} = \mu_{max} f_{lim} f_{nh} Y_{asn}
\]  

(17)

Ammonia is initially produced at a rate depending on asparagine consumption and consumed by the cells at later stage of the culture as shown in Eq (18). \( Y_{amm/asn} \) is the yield of ammonia from asparagine metabolism (mmol mmol\(^{-1} \)). However, \( Y_{amm}(mmol cell^{-1} h^{-1}) \) is ammonia consumption rate which is triggered when its concentration increases beyond \( K_{amm} \) (3.5 mM) for our system.

\[
Q_{amm} = Q_{asn} Y_{amm/asn} - Y_{amm} \frac{C_{amm}}{k_{amm} + C_{amm}}
\]  

(18)

In Eq (19), glucose is consumed by cell growth and maintenance-nongrowth-dependent terms [87–89]. The maintenance term, \( m_{glc} \) (mmol cell\(^{-1} \) h\(^{-1} \)), is the consumption rate for glucose that does not depends on cell growth rate. Eq (20) shows lactate production from glucose in the early stages of the culture with a shift to consumption after peak viable cell density has been reached [90]. \( Y_{lac/glc} \) is the conversion factor for lactate from glucose (mmol mmol\(^{-1} \)). The maintenance term of lactate \( m_{lac} \) is negative and lactate consumption does not depend on the
growth rate.

\[ Q_{\text{glc}} = \mu_{\text{max}} f_{\text{inh}} Y_{\text{glc}} + m_{\text{glc}} \]  

(19)

\[ Q_{\text{lac}} = Q_{\text{glc}} Y_{\text{lac}}/\text{glc} - m_{\text{lac}} \]  

(20)

The rest of the amino acids are produced such as alanine, glutamine and consumed such as glutamate which follow a simpler kinetics that depends on growth rate as shown in Eqs (21)–(23), respectively. The yields in these equation \( Y_{\text{ala}}, Y_{\text{gln}} \) and \( Y_{\text{glu}} \) (\( \text{mmol cell}^{-1} \)) and \( Q \) (\( \text{mmol cell}^{-1} \ h^{-1} \)).

\[ Q_{\text{ala}} = \mu_{\text{max}} f_{\text{inh}} Y_{\text{ala}} \]  

(21)

\[ Q_{\text{gln}} = \mu_{\text{max}} f_{\text{inh}} Y_{\text{gln}} \]  

(22)

\[ Q_{\text{glu}} = \mu_{\text{max}} f_{\text{inh}} Y_{\text{glu}} \]  

(23)

The following mass balances equations are used to calculate the concentration of the substrates and metabolites including the salts which were used to calculate osmolality. They show a single parameter to account for a consumption or a production rate.

\[ \frac{d[V C_{\text{asq}}]}{dt} = -Q_{\text{asq}} V N + F_{\text{in}} C_{\text{Feed-asq}} - C_{\text{asq}} F_{\text{out}} \]  

(24)

\[ \frac{d[V C_{\text{amin}}]}{dt} = Q_{\text{amin}} V N - C_{\text{amin}} F_{\text{out}} \]  

(25)

\[ \frac{d[V C_{\text{lac}}]}{dt} = Q_{\text{lac}} V N - C_{\text{lac}} F_{\text{out}} \]  

(26)

\[ \frac{d[V C_{\text{glc}}]}{dt} = -Q_{\text{glc}} V N + F_{\text{in}} C_{\text{Feed-glc}} - C_{\text{glc}} F_{\text{out}} \]  

(27)

\[ \frac{d[V C_{\text{gln}}]}{dt} = Q_{\text{gln}} V N - C_{\text{gln}} F_{\text{out}} \]  

(28)

\[ \frac{d[V C_{\text{glu}}]}{dt} = -Q_{\text{glu}} V N + F_{\text{in}} C_{\text{Feed-glu}} - C_{\text{glu}} F_{\text{out}} \]  

(29)

\[ \frac{d[V C_{\text{ala}}]}{dt} = -Q_{\text{ala}} V N - C_{\text{ala}} F_{\text{out}} \]  

(30)

\[ \frac{d[V C_{\text{Na}}]}{dt} = -Q_{\text{Na}} V N - C_{\text{Na}} F_{\text{out}} \]  

(31)

\[ \frac{d[V C_{K}]}{dt} = -C_{K} F_{\text{out}} \]  

(32)
2.1.5 mAb and host cell proteins. Our experimental data support that specific mAb productivity is constant and independent of cell growth rate, as shown in Eq (34). This reduces the number of used parameters and allows for direct comparison of \( m_{mAb} \) under the two culture temperatures.

\[
Q_{mAb} = m_{mAb}
\]  

\[
\frac{d[V mAb]}{dt} = Q_{mAb} V N - C_{mAb} F_{out}
\]  

Based on our experimental data, we hypothesise that there are two sources of HCPs, one being secretion from viable cells (at a constant rate of \( q_{HCP} \) in \( g \) cell\(^{-1} \) h\(^{-1} \)) and the second being lysis of dead cells (at a constant volumetric rate of \( q_{HCP(2)} \)) as shown in Eq (35). The cell volume is taken into account in the prediction of HCP release from dead cells by the inclusion of the average normalised cell volume \( \bar{v} \) in Eq (35). As cells increase in volume, the host cell protein content per cell also increases. To account for this, we consider \( q_{HCP(2)} \) on a per unit cell volume basis, such that, when multiplied by the cell volume, we obtain a more accurate estimate of released HCPs. Measuring the proportion of secreted and non-secreted HCPs experimentally is very challenging. As these proteins degrade during cell culture through the proteolytic activity of certain HCPs, ELISA measurements could also lead to underestimation of HCP concentration [91]. The release of intracellular content from a dead cell (i.e., DNA and HCPs) does not seem to be an immediate process and depends on the physical properties of the bioreactor, cell size and cell membrane fluidity and resistance to shear stress. Pluronic F68 is known to reduce the plasma-membrane fluidity of cells and this has been suggested as a possible mechanism of protection against shear force [92,93]. For the purpose of this model, we have chosen to neglect HCP degradation in the supernatant due to the inability to accurately determine the associated rate from existing experimental data.

\[
\frac{d[V HCP]}{dt} = q_{HCP} V N + q_{HCP(2)} V \bar{v}(N_i + N_d)
\]  

2.1.6 Temperature shift. There are three different ways to describe the effect of variation in pH and temperature on cell culture dynamics. Firstly, obtaining separate sets of parameter values each for a different set of culture conditions, which is adopted herein. The second method is to use a continuous function for a wider design space [94,95], e.g. by describing maximum cell growth rate as a continuous function of temperature using the Arrhenius and Eyring equations [96]. The third method is based on statistical modelling to derive a correlation from experimental data or other common equation for the pH such as Henderson-Hasselbalch [89,97,98].

2.1.7 Culture osmolality. The data from the four bioreactor runs were used to formulate an equation that can estimate the osmolality of CHO culture based on the values of certain key extracellular components that are routinely measured, namely glucose, lactate, \( \text{Na}^+ \) and \( \text{K}^+ \). Osmolality (\( \text{Osm} \), in mOsm kg\(^{-1} \)) is approximated by Eq (36) which has three parameters determined using the experimental datasets. Eq (36) is only applicable for our commercially available CHO cell culture medium; however, the same approach can be used to form an equation of osmolality for other systems. The terms \( \alpha_1 \), \( \alpha_2 \) and \( \alpha_3 \) equal 1.48, 0.70 and 2.18 respectively with unit of mOsm kg\(^{-1} \) mM\(^{-1} \). Many other similar osmolality equations can be found in...
the literature [99].

\[
Osm = x_1(C_{Glc}) + x_2(C_{Lac}) + x_3(C_{Na^+} + C_{K^+})
\]  

(36)

The mean absolute percentage error (MAPE) is 2.5%, which is deemed acceptable [100].

2.2 Experimental materials and methods

2.2.1 Bioreactor operation. Briefly, CHO GS46 producing chimeric IgG4 antibody (Lonza Biologics) was revived and cultured in shake flasks (Corning, NY) of CD CHO medium (Life Technologies, UK) and shaken at 140 RPM as described in [11,101]. The selective agent MTX was added to the revived cells and the first subculture. Cells were subcultured in fresh medium every 4 days at a seeding density of \(2 \times 10^5\) cells/mL. Then, bioreactor (Applikon Biotechnology, Schiedam, the Netherlands) was inoculated at a seeding density of \(3 \times 10^5\) cells/mL with an initial cell culture volume of 1.2 L. The temperature, pH and dissolved oxygen were controlled at 36.5˚C, 7.0 and 50% respectively. The bioreactor was supplemented with CD EfficientFeed™ C AGT™ (Life Technologies, UK) at 10% cell culture volume on alternate days starting from 2nd day. Two of the bioreactors were kept at 36.5˚C (sometimes refer to as 37˚C or physiological temperature in this work) whereas the other two were shifted to 32˚C on the 5th day. The cell density and diameter were measured daily using NucleoView NC-250 (ChemoMetec, Denmark). All cells below 5 and greater than 22 μm were removed as they do not represent the viable CHO cells but outliers as a result of cell aggregation and fragmentation [65,102]. The cell volume was calculated based on the diameter value assuming a spherical cell shape. The cell volume was normalised to represent values from 0 to 1 cell volume domain. The Distribution Fitter tool of MATLAB (R2017B) was used to generate the probability density function of that cell volume distribution.

2.2.2 Extracellular metabolite analysis. The protocol is taken from Sellick et al. metabolite profiling study [103,104]. The procedure is as follow:

**Sample derivatisation.** 20 μL of the cell culture supernatant was withdrawn from a fully thawed 1 mL sample tube and mixed with 200 μL of (water/methanol/isopropanol at a volume ratio of 2/5/2). The tube containing the supernatant was placed in a vacuum rotary centrifuge at 30˚C for 30 minutes to dry out completely until a metabolite pellet was observed at the bottom of the tube. The dried pellet was derivatised by addition of 10 μL methoxamine hydrochloride (MOX, 40 mg/mL in pyridine). The sample was incubated for 90 minutes at 30˚C with gentle shaking. The sample was then trimethylsilated by addition of 90 μL N-methyl-N-(trimethylsilyl) trifluoroacetamide (MSTFA) containing 1% (v/v) trichloromethylsilane (TMCS). The sample was then incubated at 37˚C for 30 minutes. The derivatised sample was cooled to room temperature and 70 μL was pipetted in silanised GC vials (National Scientific).

**GS-MS analysis.** The analysis was performed in a 7890A GC system (Agilent Technologies) coupled to a 5975C Inter XL MSD with Triple-Axis Detector (Agilent Technologies). The injected sample was 1 μL with 10:1 split ratio on a DB-5MS + DG column (Agilent Technologies; 250 μm x 30 m x 0.25 μm thickness with 10 m DuraGuard) with helium as a carrier gas. Analytes were separated by isothermal chromatography at 60˚C for a minute, then increased at a rate of 10˚C per minutes to approach 325˚C and remain at this value for further 10 minutes. The temperatures of the injector, MS source and MS quad were set at 250, 230 and 150˚C respectively. The analyte peaks in the raw chromatograms were identified using MSD ChemStation (Agilent Technologies) to search the Agilent Fiehn GC/MS. Identification was based on the RTs and fragmentation patterns. Peak areas were determined with reference to myristic acid as an internal standard for all amino acids.

**Analysis of other metabolites.** BioProfile FLEX (Nova Biomedical, MA, USA) was used to measure the concentrations of glucose, lactate, glutamine, glutamate and ammonia in cell
culture supernatants. The instrument performed automated enzymatic assays on glucose, lactate, glutamine, and glutamate, while ammonia concentration was measured by electrochemical means with a phosphate assay.

2.2.3 mAb titre. The concentration of the mAb product was measured using the Blitz system (Pall ForteBio Europe, Portsmouth, UK). The biosensor was first hydrated in sample diluent (Pall ForteBio Europe, Portsmouth, UK) for 30 minutes and then locked onto the BLItz instrument. 4μL of the sample were pipetted onto the sample holder and analysed. For each run, the binding rate was measured for 60s and concentration of the sample was directly proportional to the binding rate. A standard curve of mAb concentration was plotted against the binding rate to interpolate the corresponding titre.

2.2.4 Osmolality. The osmolality of the supernatant was measured by Osmomat 3000 (Gonotec, Berlin, Germany) based on freezing point. The equipment was calibrated with 0, 300 and 800 mOsm kg⁻¹ solutions and sample sizes were 50 μL each in 500 μL measuring vessels (Gonotec, Berlin, Germany). Duplicate measurements were taken for each sample.

2.2.5 LDH and DNA analysis. Lactate dehydrogenase (LDH) is used to identify and quantify dead cell population [105]. The Pierce™ LDH Cytotoxicity Assay Kit (Thermo Scientific™) was used to quantify the cell lysis rate. Cell culture supernatant samples were placed in 96-well flat bottom plates. Firstly, a serial dilution of cells was made from 2×10⁵ to 2.5×10⁴ cells per mL in 100 μL triplicate wells including medium to measure background activity. After that, 10 μL lysis buffer was added to all wells including cell culture supernatant samples and incubated at 37˚C for 45 minutes.

50 μL of each well was transferred to a new plate and mixed with 50 μL Reaction Mixture. After a 30-minute room temperature dark incubation, reactions were stopped by adding 50 μL Stop Solution to each well. Absorbance at 490 nm and 680 nm were measured using a plate-reading spectrophotometer to determine each sample LDH activity. The absorbance reading at 680 was subtracted from that at 490 to eliminate any background signal from the equipment.

Quant-iT™ PicoGreen™ dsDNA Assay Kit (Invitrogen™) was used to quantify double stranded DNA in the supernatant. Calibration curve of Lambda DNA was made in the range from 0 to 1 μg/mL which is described as high-range standard curve in the protocol. Every 96-well microplate included samples to construct the calibration curve and three technical replicates. The volume of the sample was 200 μL which was mixed with same volume of Diluted Quant-iT™ PicoGreen™ Reagent and incubated for 5 minutes at room temperature in dark. Fluorescence was then measured in a microplate reader (excitation at 485 nm, emission at 520 nm).

2.2.6 Cell volume data analysis. Plotting the average cell size as a function of osmolality illustrates the effect of osmolality on cell volume. Outliers in cell size, such as cell aggregates and fragments observed particularly in late-stage culture, were removed from the data. The range was limited to diameters between 10 and 20 μm based on previous observations [32,65]. The approximated non-linear function, Eq (37) was obtained using the curve fitting option in OriginLab, in which y is the average cell volume or SD of cell volume and x is the osmolality. The same equation can be used to correlate the standard deviation of the cell volume as a function of osmolality and both sets of parameter values are given in S1 Table. The best fit was given by dose response and Boltzmann function in both cases. Dose dependence of osmolality effects on many cellular variables has been already mentioned in the literature [34,65,106].

\[
y = A_1 + \frac{(A_2-A_1)}{(1+10^{|(x-x_0)/p|})}
\]  

(37)

Regardless of the bioreactor temperature, the size growth evolution follows a similar trend.
However, although there appears to be a correlation between osmolality and cell volume, this is not sufficient to fully describe the data presented herein. It is important to highlight the fact that the variation in cell volume is narrower for the biological replicates but utilising the two temperatures datasets is crucial to cover the wider range of volume distribution.

### 2.3 Parameter estimation

The model equations are solved in the gPROMS 5.0.1 model building environment (Process Systems Enterprise, [www.psenterprise.com/products/gproms](http://www.psenterprise.com/products/gproms), 1997–2020). Our PBM was solved by backward finite difference method (BFDM), which is known to be appropriate this type of integral, partial differential, and algebraic equations (IPDAEs) systems [107]. In this study, parameters estimation is obtained by the maximum likelihood method from gPROMS which attempts to determine values for the uncertain physical and variance model parameters that maximise the probability that the model will predict the experimentally measured values. The statistical constant and linear variance models were used. The 95% confidence intervals for estimated parameters were deemed satisfactory at 10% of the final parameter values [108].

### 3 Results and discussion

#### 3.1 The PBM accurately describes the experimental data

The model simulation results are compared with experimental data for the physiological temperature and mild hypothermic culture conditions in Fig 1. The viable cell density in Fig 1A is well captured even during the last a few days of the culture when kinetic models typically fail to capture the decline in cell growth rate in the presence of nutrients. The reduction in viable and dead cell densities as temperature was decreased is also captured well. However, the agreement for dead cells in Fig 1B is less satisfactory for the physiological case as the cell lysis rate might not be constant during the culture potentially due to the extracellular accumulation of intracellular components that may promote faster degradation. At the lower temperature, the dead cell profile has very large standard deviation in the second half of the culture, signifying the high biological variability in quantifying dead cells in comparison to viable ones. It is worth mentioning that the cell death rate is a non-linear function of the growth rate. Although several other cell death formulae can be used, the selected one requires fewer parameters to be estimated. The disadvantage is that the reduction in cell growth rate is not always matched by an increase in dead cell population.

The mAb and HCP concentrations are captured well as shown in Fig 1C and 1D. In the case of mAb concentration, there is some discrepancy in the final days of culture, which may be due to product release during cell death. The model accurately describes HCP accumulation, although there is increased variability in HCP measurement in late-stage culture, which is in line with the biological variability evident in dead cell density measurements. Culture osmolality is higher for the mild hypothermic case in Fig 1E because the feeding regime is the same even though the cells are less metabolically active. This leads to an accumulation of overfed nutrients extracellularly. The simulation results for the remaining metabolites considered by the model, i.e., asparagine, ammonia, glutamate, glutamine and alanine, are compared to experimental data in S2 Fig. The normalised cell volume increase is shown in Fig 1F and 1G for the physiological and mild hypothermic temperatures, respectively. The significant increase in the experimentally determined values for cell volume around 250 h is believed to be due to cell aggregation. Aggregation is known to increase in the last a few days when sticky intracellular components are released from dead cells [109]. Overall, the agreement between the model simulation results and experimental data is satisfactory but can be improved if the parameter estimation strategy focused on fitting the distribution rather than the average size.
The volume distributions are shown in Fig 2A and 2B for the physiological and hypothermic cases, respectively. As the culture conditions for two sets of bioreactor runs are identical until mild hypothermia is introduced, the volume distributions are highly comparable initially. In both cases there is a gradual increase in cell size, but this is more pronounced in the cultures grown at 32˚C due to the larger increase in culture osmolality.

According to Nolan and Lee, there are six characteristics defining an ideal cell culture model [105]. One of those is being able to describe long term dynamics of the fed-batch culture. It is very challenging because a deviation between simulation results and experimental data is commonly observed in the last days of the fed-batch culture. This has led researchers to explore cell culture phase segregation to look at cell growth dynamics at these different culture phases separately [32]. The discrepancy could be because there are many variations in

Fig 1. Comparison of model simulation results with experimental data. The red and blue lines represent the model output for the physiological and mild hypothermic bioreactors, respectively. The experimental data are represented in square (physiological temperature) and circular (mild hypothermia) points for (A) viable cell density; (B) dead cell density (C) mAb titre, (D) extracellular HCP concentration, (E) culture osmolality, (F) and (G) normalised cell volume for physiological temperature and mild hypothermic case, respectively. Error bars represent one standard deviation. https://doi.org/10.1371/journal.pone.0265886.g001

The volume distributions are shown in Fig 2A and 2B for the physiological and hypothermic cases, respectively. As the culture conditions for two sets of bioreactor runs are identical until mild hypothermia is introduced, the volume distributions are highly comparable initially. In both cases there is a gradual increase in cell size, but this is more pronounced in the cultures grown at 32˚C due to the larger increase in culture osmolality.

According to Nolan and Lee, there are six characteristics defining an ideal cell culture model [105]. One of those is being able to describe long term dynamics of the fed-batch culture. It is very challenging because a deviation between simulation results and experimental data is commonly observed in the last days of the fed-batch culture. This has led researchers to explore cell culture phase segregation to look at cell growth dynamics at these different culture phases separately [32]. The discrepancy could be because there are many variations in
extracellular components such as vitamins, nucleotides, growth factors, folic acid, which are not routinely measured and less simple to account for in a model [83]. Moreover, many phenomena occur in the last days of cell culture such as cell fragmentation and lysis, and degradation of proteins. Additionally, gene regulation events may lead to less traceable phenotypes. This has also been observed by Munzer et al. who found a greater deviation in cell cycle phase prediction in late-stage culture [110].

3.2 Understanding the origin of extracellular HCPs

There are many factors that affect HCP accumulation and degradation such as culture temperature and pH [111]. Using the model presented above, we therefore sought to understand what proportion of HCPs is secreted versus released upon dead cell lysis. Given that most staining dyes do not quantify the cells that have already lysed after death, the commonly used method of trypan blue dye exclusion for determining culture viability leads to underestimation of cell death. For this reason, we employed orthogonal methods for determining cell content in the supernatant. Specifically, we measured lactate dehydrogenase (LDH) and DNA, which are released from cells with compromised membrane [112]. LDH has been used to determine necrotic cells as leakage occurs of plasma membrane [113].

From a first glance at Fig 3, extracellular LDH and DNA are higher at the physiological temperature in comparison to mild hypothermic case. This is expected as dead cell density is

![Fig 2](https://doi.org/10.1371/journal.pone.0265886.g002)

![Fig 3](https://doi.org/10.1371/journal.pone.0265886.g003)
significantly higher at physiological temperature as measured by NC-250 in Fig 1B. For both markers, the deviation between the two bioreactors increases at a higher rate after day 10.

The dead cell population (Fig 1B) increases linearly after day 5 under physiological temperature but at a much slower rate under mild hypothermia. Although this trend is observed in the DNA profile (Fig 3B) and HCP concentration (Fig 1D), this is not the case for LDH concentration until day 10. Similarly, the large increase in LDH on days 13 and 14 is not observed in the DNA or dead cell concentration profiles. More importantly, the dead cell population determined by NC-250 is five times higher for the physiological temperature bioreactor, which is not reflected in any of the values of DNA, HCP concentration apart from day 13 for LDH. The number of lysed cells estimated based on LDH quantification (Fig 3A) is approximately 60% higher than the dead cell density measured by NC-250 for the physiological temperature bioreactor runs. Interestingly, the LDH assay identified about 400% more lysed cells than dead cells on day 14 for the mild hypothermia case. Comparing the concentrations of DNA, HCP and LDH between physiological and hypothermic bioreactor runs, we see that the former are approximately two times higher than the latter for all markers. This may be due to the degradation rate of these molecules being higher at 37˚C. The degradation rate of LDH in the supernatant is known to be higher at 37˚C in comparison to 32˚C [114] and has been reported to be double that of DNA [111,115]. The degradation of HCP is also expected to be reduced at lower temperatures [116].

It is also important to look at the HCP profile which, although following the same trend with the loss of culture viability, does not correlate as well with dead cell density. It is worth noting that viable cell density at physiological temperature is double that at mild hypothermia. This could also support the hypothesis that when culture viability is high, most HCPs are secreted as noted in other studies [117–119].

It has been reported that the DNA content of a CHO cell is 1.11 pg [111], while reports of the intracellular protein content of CHO cells vary in the literature. For example, Pan et al. reported an average of 71 pg cell⁻¹, while Cheung reported a value of 82 pg cell⁻¹ [120], Kol et al. of 150 pg cell⁻¹ proteins [121] and Chaudhuri of a range from 5 to 40 pg cell⁻¹ [122] depending on the culture day. The Kol et al. value was eliminated as it is based on cells that were harvested on day 7 when culture viability was less than 90%, which is not representative of our system. The other two values were averaged and the resulting value, 75 pg cell⁻¹, was used in subsequent analysis.

As the DNA degradation rate is smaller than that of LDH and it is more stable than proteins, it was used to quantify cells that released their intracellular contents in this study. These are around 3.6 and 1.8 million cells mL⁻¹ for physiological and mild hypothermic conditions on the final day, respectively, based on Fig 3B. If all intracellular content was fully released and assuming that the protein content per cell and extracellular degradation rate at the two temperatures are the same, then, 0.27 and 0.13 mg mL⁻¹ come from the dead cells, at physiological and mild hypothermic bioreactors, respectively. The difference between these estimates and the measured concentrations (Fig 1D) is expected to have been secreted. This means that slightly more than half of the total HCPs at the end of the culture are, in fact, secreted. This is supported by the a recent study by Kol et al., who achieved a reduction of more than 50% in HCP concentration for high viability cell cultures >90% by knocking out 6 HCPs genes [121].

We used the estimates of the model parameterization exercise to further inform our analysis (parameter estimates and confidence intervals are shown in S2 Table). Because of the significant discrepancies between the measured dead cell density and cell lysis estimates derived from LDH and double stranded DNA measurements, we estimated the cell lysis rate, $k_l$, in Eq (7) based on the viable and dead cell concentration data only.

The initial guess and upper and lower bounds for the two HCP parameters were informed by the specific HCP secretion rate from viable cells estimated above and the total protein
content per cell that is released to the extracellular matrix upon cell death (as discussed above). Different secretion rates from viable cells are estimated, based on the parameter estimation (S2 Table), for the two culture temperatures: $2.4 \times 10^{-11} \text{ g cell}^{-1} \text{ h}^{-1}$ at physiological temperature and $3.4 \times 10^{-14} \text{ g cell}^{-1} \text{ h}^{-1}$ for mild hypothermic temperature. This could mean that metabolically active cells at higher cell density secrete HCPs at a higher rate for biologically known purposes such as for cell signaling. Considering the higher dead cell density at 36.5˚C, a higher proportion of extracellular HCP concentration is estimated to be released from non-viable cells. However, based on the estimated value of the HCP production rate from dead and lysed cells, mild hypothermia seems to either increase cellular HCP content or slow down the degradation of HCP in comparison to physiological temperature, S2 Table. It should be noted that the release and degradation of HCPs after death is expected to proceed at a higher rate at physiological temperature, assuming that the dead cell density at both temperatures has been accurately determined. It is worth mentioning that many approaches for estimating $q_{\text{HCP}}$ and $q_{\text{HCP}}^{(2)}$ were explored such as simultaneous estimation of the parameters and one parameter at a time. Our estimated values give the best fitting quality considering the HCP profile. It appears difficult to draw any firm conclusions without experimentally establishing the degradation rate of HCPs at the different temperatures and how culture temperature affects the intracellular HCP content of CHO cells. Another challenge stems from the fact that HCPs have a wide range of half-lives [123,124]. Nonetheless, our analysis shows that the assumption that extracellular HCPs mostly derive from dead cells, as various publications claim [125], can only hold true for culture viability values well below 80%.

### 3.3 Using the model to perform in silico optimisation.

The trained model has been used to maximise different objective functions with certain technical and economical constraints applied to determine possible process operation scenarios. In this optimisation problem four scenarios were looked at as summarised in Table 1. Physiological temperature growth scenarios are given in the first two rows and the temperature shift scenarios follow. Cases 1 and 4 are the control experiments (standard cases) for the physiological and mild hypothermic conditions, respectively, which were used for parameter estimation only. No feed is introduced in the first 48 hours of culture in line with the feeding regime used for model parameterisation. The minimum acceptable viability in this case is 80%, which reflects common industrial practice as cell death leads to release of cell-derived impurities such as DNA, HCP and product with immature glycosylation [126].

Feeding of all amino acids is recommended to maintain consistent nutrient availability. This strategy is implemented to achieve higher cell density and protein production [127–129]. The concentrations of amino acids and glucose are not set as degrees of freedom, unlike in Kappatou et al. [126], as the model has been verified with data from processes using commercially available feed and extrapolation to different conditions may not be valid. Separating

Table 1. A summary of mAb optimisation scenarios.

| Case | Description |
|------|-------------|
| 2    | Max [mAb], subject to: |
|      | * Viability $\geq$ 80% |
|      | * Feed in $= 0$, $t \leq 48$ h |
|      | * Control variable $\in [10,40]$ |
|      | * $1.1 \leq V \leq 1.3$ L |
|      | * $0 \leq$ Feed in $\leq 120$ mL/day |
|      | * Feed out $= 55$ mL/day |
| 3    | Max [mAb/HCP] |
|      | * The same previous constraints are applied. |
| 5    | Max [mAb], with the same constraints of Case 2 |
| 6    | Max [mAb/HCP] |
|      | * The temperature switch time point (found to be 140 hours) |

https://doi.org/10.1371/journal.pone.0265886.t001
glucose and growth-limiting amino acids form the rest of the nutrients might be recommended as shown in the study by Xing et al. [4]. However, this was not considered in this study.

The outcome of the optimisation studies is compared to the respective control experiment in Fig 4. The 80% culture viability constraint has not been violated for any of the optimised cases (Fig 4A) but cultures at mild hypothermic conditions (cases 5 and 6) sustain a higher viability for longer compared to those at physiological temperature (cases 2 and 3), as shown in Fig 4B. The 80% viability constraint results in earlier harvest time for cases 2 and 3 (Fig 4C).
For the mild hypothermia case, the titre increase is related to the relatively longer culture duration when the objective of the optimization strategy is to maximise mAb titre. However, if product/impurity ratio is chosen as the objective function, the culture duration is slightly reduced to achieve higher viability and product:HCP concentration ratio. If the chromatography columns are designed to withstand relatively high impurities feedstock, then case 5 seems the best choice. Otherwise, case 6 might be more attractive, but more financial assessments should be done in the downstream unit operations to evaluate the lifetime and cost associated to Protein A chromatography column was and regeneration frequency. Finally, Fig 4E and 4F depict the effect of changing the objective function to include the impurity concentration as a decision criterion.

The time of the temperature downshift is critical as cell growth is significantly slower at reduced temperatures. This negatively affects the attainable viable cell density and hence the mAb titre. However, mild hypothermia offers a culture duration extension to compensate the drop in titre, reduced consumption of nutrients and decreased accumulation of waste products [130,131]. Nolan and Lee looked at several scenarios such as feeding strategy, day of temperature shift, initial seeding density. Based on their study, the effect of lower seeding density is similar to early temperature shift in affecting viable cell density and suppress the lactate shift [105].

4 Conclusion
This study shows the usefulness of mathematical modelling for exploring trade-offs in bioprocess performance. Integrating this model with a downstream purification model to evaluate the cost of removing these fractions of impurities, can help determine what concentration of HCPs can be economically tolerated in the cell culture supernatant and aid whole bioprocess design. While the PBM was improved by including the cell volume increase which can be readily implemented in future studies, the content of HCPs per unit cell volume at the two growth temperatures should be identified experimentally to improve the quantification of secreted and non-secreted HCP production and their degradation rate in the supernatant at different cell culture temperatures.

Supporting information
S1 Fig. Division function for a mean of 0.5 and three different SD. (DOCX)
S2 Fig. The model fitting for the main metabolites and substrate for the physiological (dark red) and mild hypothermia (light red). The black and grey experimental data correspond to the physiological and mild hypothermia respectively. Glucose(A), Lactate(B), Asparagine(C), Ammonia(D), Glutamate(E) Glutamine(F) Alanine(G). (DOCX)
S1 Table. Parameter values for Eq (37). (DOCX)
S2 Table. Parameter values with their 95% confidence interval and units. (DOCX)

Acknowledgments
SA would like to thank King Abdulaziz University for his scholarship. We would like to thank Alan Dickson and Mark Elvin (University of Manchester) and Alexandros Kiparissides...
(University College London) for allowing us to use their laboratories for osmolality and amino acid analyses.

**Author Contributions**

**Formal analysis:** Sakhr Alhuthali.

**Funding acquisition:** Sakhr Alhuthali, Cleo Kontoravdi.

**Supervision:** Cleo Kontoravdi.

**Visualization:** Sakhr Alhuthali.

**Writing – original draft:** Sakhr Alhuthali.

**Writing – review & editing:** Sakhr Alhuthali, Cleo Kontoravdi.

**References**

1. Mahmuda A, Bande F, Al-Zihiry KJK, Abdulhaleem N, Abad Majid R, Hamat RA, et al. Monoclonal antibodies: A review of therapeutic applications and future prospects. Tropical Journal of Pharmaceutical Research. 2017; 16(3):713–22. https://doi.org/10.4314/tjpr.v16i3.29 WOS:000399247000029.

2. Walsh G. Biopharmaceutical benchmarks 2018. Nature Biotechnology. 2018; 36(12):1136–45. https://doi.org/10.1038/nbt.4305 WOS:000452395100008. PMID: 30520869.

3. Park JH, Jin JH, Lim MS, An HJ, Kim JW, Lee GM. Proteomic Analysis of Host Cell Protein Dynamics in the Culture Supernatants of Antibody-Producing CHO Cells. Scientific Reports. 2017; 7. ARTN 44246 https://doi.org/10.1038/srep44246 WOS:000396318500001. PMID: 28281648.

4. Xing Z, Kenty B, Koyrakh I, Borys M, Pan SH, Li ZJ. Optimizing amino acid composition of CHO cell culture media for a fusion protein production. Process Biochemistry. 2011; 46(7):1423–9. https://doi.org/10.1016/j.procbio.2011.03.014 WOS:000292411700006.

5. Zhang J, Siva S, Caple R, Ghose S, Gronke R. Maximizing the Functional Lifetime of Protein A Resins. Biotechnology Progress. 2017; 33(3):708–15. https://doi.org/10.1002/btpr.2448 WOS:000403882900014. PMID: 28218470.

6. Goey CH, Alhuthali S, Kontoravdi C. Host cell protein removal from biopharmaceutical preparations: Towards the implementation of quality by design. Biotechnology Advances. 2018; 36(4):1223–37. https://doi.org/10.1016/j.biotechadv.2018.03.021 WOS:000435619800024. PMID: 29654903.

7. Gilgunn S, Bones J. Challenges to industrial mAb bioprocessing—removal of host cell proteins in CHO cell bioprocesses. Current Opinion in Chemical Engineering. 2018; 22:98–106. https://doi.org/10.1016/j.coche.2018.08.001 WOS:000454025900014.

8. Goey CH, Bell D, Kontoravdi C. Mild hypothermic culture conditions affect residual host cell protein composition post-Protein A chromatography. mAbs. 2018; 10(3):476–87. https://doi.org/10.1080/19420862.2018.1433977 PMCID: 29381421.

9. Vanderlaan M, Zhu-Shimoni J, Lin SS, Gunawan F, Waermer T, Van Cott KE. Experience with Host Cell Protein Impurities in Biopharmaceuticals. Biotechnology Progress. 2018; 34(4):828–37. https://doi.org/10.1002/btpr.2640 WOS:000463306200001. PMID: 29693803.

10. Yang B, Li WH, Zhao H, Wang AL, Lei YJ, Xie QL, et al. Discovery and characterization of CHO host cell protease-induced fragmentation of a recombinant monoclonal antibody during production process development. Journal of Chromatography B-Analytical Technologies in the Biomedical and Life Sciences. 2019; 1112:1–10. https://doi.org/10.1016/j.jchromb.2019.02.020 WOS:000463306200001. PMID: 30836312.

11. Goey CH, Tsang JMH, Bell D, Kontoravdi C. Cascading effect in bioprocessing-The impact of mild hypothermia on CHO cell behavior and host cell protein composition. Biotechnology and Bioengineering. 2017; 114(12):2771–81. https://doi.org/10.1002/bit.26437 WOS:000413664900008. PMID: 28843000.

12. Koutinas M, Kiparisissides A, Pistikopoulos EN, Mantalaris A. Bioprocess systems engineering: transferring traditional process engineering principles to industrial biotechnology. Comput Struct Biotechnol J. 2012; 3:e201210022. https://doi.org/10.5936/csbi.201210022 PMID: 24688682; PubMed Central PMCID: PMC3962201.

13. Sou SN, Jedrzejewski PM, Lee K, Sellick C, Polizzi KM, Kontoravdi C. Model-based investigation of intracellular processes determining antibody Fc-glycosylation under mild hypothermia. Biotechnology and Bioengineering. 2017; 114(7):1570–82. https://doi.org/10.1002/bit.26225 PMID: 27869292.
14. Galluzzi L, Aaronson SA, Abrams J, Alnemri ES, Andrews DW, Baehrecke EH, et al. Guidelines for the use and interpretation of assays for monitoring cell death in higher eukaryotes. Cell Death and Differentiation. 2009; 16(8):1093–107. https://doi.org/10.1038/cdd.2009.44 PMID: 19373242

15. Tait AS, Tarrant RD, Velez-Suberbie ML, Spencer DI, Bracewell DG. Differential response in downstream processing of CHO cells grown under mild hypothermic conditions. Biotechnology progress. 2013; 29(3):688–96. https://doi.org/10.1002/btp.1726 PMID: 23636936

16. Bucalá V, Piña J. Teaching population balances for CHE students: Application to granulation processes. Chemical Engineering Education. 2007; 41(3):209–17.

17. Nopens I, Torfs E, Ducoste J, Vanrolleghem PA, Gernaey KV. Population balance models: a useful complementary modelling framework for future WWTP modelling. Water Science and Technology. 2015; 71(2):159–67. WOS:000350877100013.

18. Waldherr S. Estimation methods for heterogeneous cell population models in systems biology. Journal of the Royal Society Interface. 2018; 15(147). ARTN 20180530 https://doi.org/10.1098/rsif.2018.0530 WOS:000448813900025. PMID: 30381346

19. Ahmad W, Kuitunen S, Sixta H, Alopaeus V. Population balance based modeling of changes in celluose molecular weight distribution during ageing. Cellulose. 2015; 22(1):151–63. WOS:000350877100013.

20. Engel P, Bonhage B, Pernik D, Rinaldi R, Schmidt P, Wulfhorst H, et al. Population balance modelling of homogeneous and heterogeneous cellulose hydrolysis. 21st European Symposium on Computer Aided Process Engineering. 2011; 29:1316–20. WOS:000294218900263.

21. Jeldres RI, Concha F, Toledo PG. Population balance modelling of flocculation with attention to aggregate restructuring and permeability. Advances in Colloid and Interface Science. 2015; 224:62–71. WOS:000362060700005. https://doi.org/10.1016/j.cis.2015.07.009 PMID: 26253811

22. Fernandes RL, Niercycho M, Lundin L, Pedersen AE, Tellez PEP, Dutta A, et al. Experimental methods and modeling techniques for description of cell population heterogeneity. Biotechnology Advances. 2011; 29(6):575–99. https://doi.org/10.1016/j.biotechadv.2011.03.007 WOS:000296821900003. PMID: 21540103

23. Solvik J, Jakobsen HA. The Foundation of the Population Balance Equation: A Review. Journal of Dispersion Science and Technology. 2015; 36(4):510–20. https://doi.org/10.1080/01932691.2014.909318 WOS:000345316300007.

24. Świerniak A, Kimmel M, Smieja J, Puszynski K, Psiuk-Maksymowicz K. Structured Models and Their Use in Modeling Anticancer Therapies. System Engineering Approach to Planning Anticancer Therapies. Cham: Springer International Publishing; 2016. p. 85–138.

25. Subramanian G,Ramkrishna D, Fredrickson AG, Tsuchiya HM. On the mass distribution model for microbial cell populations. Bull Math Biophys. 1970; 32(4):521–37. https://doi.org/10.1007/BF02476789 PMID: 5513392.

26. Mantzaris NV, Daoutidis P. Cell population balance modeling and control in continuous bioreactors. Journal of Process Control. 2004; 14(7):775–84. https://doi.org/10.1016/j.procont.2003.12.001 WOS:000222103000006.

27. Mantzaris NV, Srienc F, Daoutidis P. Control of cell mass distribution in continuous bioreactors using population balance models. Dynamics & Control of Process Systems 1998, Volumes 1 and 2. 1999:571–6. WOS:000084435300089.

28. Zhu GY, Zamamiri A, Henson MA, Hjortso MA. Model predictive control of continuous yeast bioreactors using cell population balance models. Chemical Engineering Science. 2000; 55(24):6155–67. https://doi.org/10.1016/S0009-2509(00)00208-6 WOS:000165959600018.

29. Quevedelle V, Ouazzaite H, Polizzi B, Fox RO, Villedieu P, Fede P, et al. A two-dimensional population balance model for cell growth including multiple uptake systems. Chemical Engineering Research & Design. 2018; 132:966–81. https://doi.org/10.1016/j.chemer.2018.02.025 WOS:000430522300082.

30. Mantzaris NV, Srienc F, Daoutidis P. Nonlinear productivity control using a multi-stage cell population balance model. Chemical Engineering Science. 2002; 57(1):1–14. https://doi.org/10.1016/S0009-2509(01)00356-6 WOS:000173673800001.

31. Ekman JM, Fredrickson AG, Tsuchiya HH. Statistics and dynamics of microbial cell populations. Chem Eng Prog Symp Ser. 1966; 62:37–49.

32. Pan X, Dalm C, Wijffels RH, Martens DE. Metabolic characterization of a CHO cell size increase phase in fed-batch cultures. Applied Microbiology and Biotechnology. 2017; 101(22):8101–13. WOS:000413685300004. https://doi.org/10.1007/s00253-017-8531-y PMID: 28951949
Bertucco A, Sforza E, Fiorenzato V, Strumendo M. Population balance modeling captures host cell protein dynamics in CHO cell cultures.

33. Seewoster T, Lehmann J. Cell size distribution as a parameter for the predetermination of exponential growth during repeated batch cultivation of CHO cells. Biotechnology and Bioengineering. 1997; 55(5):793–7. WOS:A1997NX12400009. https://doi.org/10.1002/(SICI)1097-0290(19970905)55:5<793::AID-BT9>3.0.CO;2-6 PMID: 18636589

34. Alhuthali S, Kotidis P, Kontoravdi C. Osmolality Effects on CHO Cell Growth, Cell Volume, Antibody Productivity and Glycosylation. International Journal of Molecular Sciences. 2021; 22(7):3290. https://doi.org/10.3390/ijms22073290 PMID: 33804825

35. Rehberg M, Ritter JB, Genzel Y, Flockerzi D, Reichl U. The relation between growth phases, cell volume changes and metabolism of adherent cells during cultivation. Journal of Biotechnology. 2013; 164(4):489–99. https://doi.org/10.1016/j.jbiotec.2013.01.018 WOS:000317187800007. PMID: 23434835

36. Bertucco A, Sforza E, Fiorenzato V, Strumendo M. Population balance modeling of a microalgal culture in photobioreactors: Comparison between experiments and simulations. Aiche Journal. 2015; 61(9):2702–10. WOS:000359311100004.

37. Takagi M, Hayashi H, Yoshida T. The effect of osmolality on metabolism and morphology in adhesion and suspension Chinese hamster ovary cells producing tissue plasminogen activator. Cytotherapy. 2000; 32(3):171–9. https://doi.org/10.1023/A:1008171921282 WOS:000086620300001. PMID: 19002978

38. Zhu MM, Goyal A, Rank DL, Gupta SK, Vanden Boom T, Lee SS. Effects of elevated pCO2 and osmolality on growth of CHO cells and production of antibody-fusion protein B1: a case study. Biotechnol Prog. 2005; 21(1):70–7. https://doi.org/10.1021/bp049815a PMID: 15930242.

39. Pfizenmaier J, Matuszczyk JC, Takors R. Changes in intracellular ATP-content of CHO cells as response to hyperosmolality. Biotechnology Progress. 2015; 31(5):1212–6. https://doi.org/10.1002/btpr.2143 WOS:000363689200009. PMID: 26146937

40. Fadda S, Cinotti A, Cao G. A novel population balance model to investigate the kinetics of in vitro cell proliferation: Part II. numerical solution, parameters’ determination, and model outcomes. Biotechnology and bioengineering. 2012; 109(3):782–96. https://doi.org/10.1002/bit.24350 PMID: 22012749

41. Ramkrishna D. Population balances theory and applications to particulate systems in engineering. Amsterdam; London: Elsevier/Academic; 2000. Available from: http://www.engineeringvillage.com/controller/servlet/OpenURL?genre=book&isbn=9780125768709.

42. Bi JX, Shuttleworth J, Al-Rubeai M. Uncoupling of cell growth and proliferation results in enhancement of productivity in p21CIP1-arrested CHO cells. Biotechnology and bioengineering. 2004; 85(7):741–9. https://doi.org/10.1002/bit.20025 PMID: 14991652

43. Marshall WF, Young KD, Swaffer M, Wood E, Nurse P, Kimura A, et al. What determines cell size? BMC biology. 2012; 10(1):1–22. https://doi.org/10.1186/1741-7007-10-101 PMID: 23241366

44. Levy DL, Heald R. Mechanisms of intracellular scaling. Annual review of cell and developmental biology. 2012; 28:113–35. https://doi.org/10.1146/annurev-celbio-092910-154158 PMID: 22804576

45. Marguerat S, Schmidt A, Codlin S, Chen W, Aebersold R, Bähler J. Quantitative analysis of fission yeast transcriptomes and proteomes in proliferating and quiescent cells. Cell. 2012; 151(3):671–83. https://doi.org/10.1016/j.cell.2012.09.019 PMID: 23101633

46. Pfizenmaier J, Matuszczyk JC, Takors R. Changes in intracellular ATP-content of CHO cells as response to hyperosmolality. Biotechnology Progress. 2015; 31(5):1212–6. https://doi.org/10.1002/btpr.2143 WOS:000363689200009. PMID: 26146937

47. Fadda S, Cinotti A, Cao G. A novel population balance model to investigate the kinetics of in vitro cell proliferation: Part II. numerical solution, parameters’ determination, and model outcomes. Biotechnology and bioengineering. 2012; 109(3):782–96. https://doi.org/10.1002/bit.24350 PMID: 22012749

48. Ramkrishna D. Population balances theory and applications to particulate systems in engineering. Amsterdam; London: Elsevier/Academic; 2000. Available from: http://www.engineeringvillage.com/controller/servlet/OpenURL?genre=book&isbn=9780125768709.

49. Bi JX, Shuttleworth J, Al-Rubeai M. Uncoupling of cell growth and proliferation results in enhancement of productivity in p21CIP1-arrested CHO cells. Biotechnology and bioengineering. 2004; 85(7):741–9. https://doi.org/10.1002/bit.20025 PMID: 14991652

50. Marshall WF, Young KD, Swaffer M, Wood E, Nurse P, Kimura A, et al. What determines cell size? BMC biology. 2012; 10(1):1–22. https://doi.org/10.1186/1741-7007-10-101 PMID: 23241366

51. Ramkrishna D. Population balances theory and applications to particulate systems in engineering. Amsterdam; London: Elsevier/Academic; 2000. Available from: http://www.engineeringvillage.com/controller/servlet/OpenURL?genre=book&isbn=9780125768709.
52. Liu YH, Bi JX, Zeng AP, Yuan JQ. A population balance model describing the cell cycle dynamics of myeloma cell cultivation. Biotechnology Progress. 2007; 23(5):1198–209. https://doi.org/10.1021/bp070152z WOS:000250010000030. PMID: 17691814

53. Cooper S. Distinguishing between linear and exponential cell growth during the division cycle: Single-cell studies, cell-culture studies, and the object of cell-cycle research. Theoretical Biology and Medical Modelling. 2006; 3. Art10 https://doi.org/10.1186/1742-4682-3-10 WOS:000208054800010. PMID: 16504098

54. Anderson EC, Bell GI, Petersen DF, Tobey RA. Cell growth and division. IV. Determination of volume growth rate and division probability. Biophys J. 1969; 9(2):246–63. https://doi.org/10.1016/S0006-3495(69)83633-6 PMID: 576232; PubMed Central PMCID: PMC1367431.

55. Aiba S, Endo I. Statistical Analysis of Growth of Microorganisms. Aiche Journal. 1971; 17(3):608–12. https://doi.org/10.1002/aiic.690170324 WOS:A1971J558500017.

56. Kyriakopoulos S, Kontoravdi C. A framework for the systematic design of fed-batch strategies in mammalian cell culture. Biotechnology and Bioengineering. 2014; 111(12):2466–76. https://doi.org/10.1002/bit.25319 PMID: 24975682

57. Lopez-Mendez J, Araiz-Hernandez D, Carrillo-Cocom LM, Lopez-Pacheco F, Rocha-Pizana MD, Alvarado MM. Using simple models to describe the kinetics of growth, glucose consumption, and monoclonal antibody formation in naive and infliximab producer CHO cells. Cytotherapy. 2016; 18(4):1287–300. https://doi.org/10.1016/j.jcyt.2016.01.008-2 WOS:000380265300065. PMID: 26091615

58. Stamatakis M. Cell population balance, ensemble and continuum modeling frameworks: Conditional equivalence and hybrid approaches. Chemical Engineering Science. 2010; 65(2):1008–15. https://doi.org/10.1016/j.ces.2009.09.054 WOS:000276206800036.

59. Linardos TI, Kalogerakis N, Behie LA. Cell cycle model for growth rate and death rate in continuous suspension hybridoma cultures. Biotechnology and Bioengineering. 1992; 40(3):359–68. https://doi.org/10.1002/bit.260400305 PMID: 18601126

60. Linardos TI, Kalogerakis N, Behie LA, Lamontagne LR. The Effect of Specific Growth-Rate and Death Rate on Monoclonal-Antibody Production in Hybridoma Chemostat Cultures. Canadian Journal of Chemical Engineering. 1991; 69(2):429–38. https://doi.org/10.1002/cjce.5450690205 WOS: A1991FK15200005.

61. Chormey DS, Bakirdere S, Turan NB, Engin GÖ. Fundamentals of Quorum sensing, analytical methods and applications in membrane bioreactors. 2018.

62. Karra S, Sager B, Karim MN. Multi-Scale Modeling of Heterogeneities in Mammalian Cell Culture Processes. Industrial & Engineering Chemistry Research. 2010; 49(17):7990–8006. https://doi.org/10.1021/ie100125a

63. Szélová D, Ruckerbauer DE, Galleguillos SN, Petersen LB, Natter K, Hanscho M, et al. What CHO is made of: Variations in the biomass composition of Chinese hamster ovary cell lines. Metabolic engineering. 2019; 69(2):429–38. https://doi.org/10.1016/j.ymben.2019.06.002 WOS:000427486800004.

64. Sharifian M, Fanaei MA. Dynamic Simulation and Control of a Continuous Bioreactor Based on Cell Population Balance Model. Iranian Journal of Chemistry & Chemical Engineering-International English Edition. 2009; 28(2):15–27. WOS:000270616900002.

65. Chrysinas P, Kavousanakis ME, Boudouvis AG. Effect of cell heterogeneity on isogenic populations with the synthetic genetic toggle switch network: Bifurcation analysis of two-dimensional cell population balance models. Computers & Chemical Engineering. 2018; 112:27–36. https://doi.org/10.1016/j.compchemeng.2018.01.021 WOS:000427486800004.
71. Fadda S, Cincotti A, Cao G. A novel population balance model to investigate the kinetics of in vitro cell proliferation: Part I. model development. Biotechnology and Bioengineering. 2012; 109(3):772–81. WOS:000299154600017. https://doi.org/10.1002/bit.24351 PMID: 22081270

72. Maeno E, Takahashi N, Okada Y. Dysfunction of regulatory volume increase is a key component of apoptosis. Febs Letters. 2006; 580(27):6513–7. https://doi.org/10.1016/j.febslet.2006.10.074 WOS:000242665700034. PMID: 17101138

73. Varsano G, Wang YD, Wu M. Probing Mammalian Cell Size Homeostasis by Channel-Assisted Cell Reshaping. Cell Reports. 2017; 20(2):397–410. https://doi.org/10.1016/j.celrep.2017.06.057 WOS:000405198100011. PMID: 28700941

74. Cadart C, Monnier S, Grilli J, Saez PJ, Srivastava N, Attia R, et al. Size control in mammalian cells involves modulation of both growth rate and cell cycle duration. Nature Communications. 2018; 9. ARTN 327510.1 https://doi.org/10.1038/s41467-018-05393-0 WOS:000441768300006. PMID: 30115907

75. Zhurinsky J, Leonhard K, Watt S, Margue rat S, Bahler J, Nurse P. A coordinated global control over cellular transcription. Curr Biol. 2010; 20(22):1194–205. Epub 2010/09/17. https://doi.org/10.1016/j.cub.2010.08.053 PMID: 20970341.

76. Tanouchi Y, Pai A, Park H, Huang S, Stamatov R, Buchler NE, et al. A noisy linear map underlies oscillations in cell size and gene expression in bacteria. Nature. 2015; 523(7560):357–60. Epub 2015/06/05. https://doi.org/10.1038/nature14562 PMID: 26040722; PubMed Central PMCID: PMC4860008.

77. Goranov Al, Cook M, Ricicova M, Ben-Ari G, Gonzalez C, Hansen C, et al. The rate of cell growth is governed by cell cycle stage. Genes Dev. 2009; 23(12):1408–22. Epub 2009/06/17. https://doi.org/10.1101/gad.1777309 PMID: 19528319; PubMed Central PMCID: PMC2701574.

78. Ramirez OT, Mutharasan R. Cell cycle- and growth phase-dependent variations in size distribution, antibody productivity, and oxygen demand in hybridoma cultures. Biotechnol Bioeng. 1990; 36(8):839–48. Epub 1990/10/20. https://doi.org/10.1002/bit.260360814 PMID: 18597283.

79. Mongin AA, Orlov SN. Mechanisms of cell volume regulation and possible nature of the cell volume sensor. Pathophysiology. 2001; 8(2):77–88. Epub 2001/11/27. https://doi.org/10.1016/s0928-4680(01)00074-8 PMID: 11720802.

80. Lloyd AC. The regulation of cell size. Cell. 2013; 154(6):1194–205. Epub 2013/09/17. https://doi.org/10.1016/j.cell.2013.08.053 PMID: 24034244.

81. Spetsieris K, Zygourakis K. Single-cell behavior and population heterogeneity: solving an inverse problem to compute the intrinsic physiological state functions. J Biotechnology. 2012; 138(3):80–90. Epub 2011/09/21. https://doi.org/10.1016/j.jbiotec.2011.08.018 PMID: 21930163; PubMed Central PMCID: PMC3432406.

82. Pereira S, Kildegaard HF, Andersen MR. Impact of CHO Metabolism on Cell Growth and Protein Production: An Overview of Toxic and Inhibiting Metabolites and Nutrients. Biotechnology Journal. 2018; 13(4). UNSP 1700499 https://doi.org/10.1002/biot.201700499 WOS:000427562500018. PMID: 23939387

83. Selvarasu S, Ho YS, Chong WPK, Wong NSC, Yusufi FNK, Lee YY, et al. Combined in silico modeling and metabolomics analysis to characterize fed-batch CHO cell culture. Biotechnology and Bioengineering. 2012; 109(6):1415–29. https://doi.org/10.1002/bit.22890 WOS:000302937100014. PMID: 22252269

84. Sengupta N, Rose ST, Morgan JA. Metabolic Flux Analysis of CHO Cell Metabolism in the Late Non-Growth Phase. Biotechnology and Bioengineering. 2011; 109(1):82–92. https://doi.org/10.1002/bit.22880 WOS:000284717200009. PMID: 20672285

85. Ullonska S, Kroll P, Ercik J, Clemens C, Yoges R, Muller MM, et al. Workflow for Target-Oriented Parameterization of an Enhanced Mechanistic Cell Culture Model. Biotechnology Journal. 2016; 13(4). ARTN 1700395 https://doi.org/10.1002/biot.201700395 WOS:000430169000007. PMID: 29149549

86. del Val IJ, Fan YZ, Weilguny D. Dynamics of immature mAb glycoform secretion during CHO cell culture: An integrated modelling framework. Biotechnology Journal. 2016; 11(5):610–23. https://doi.org/10.1002/biot.201400663 WOS:000375078600004. PMID: 26743760

87. Farzan P, Ierapetritou MG. Integrated modeling to capture the interaction of physiology and fluid dynamics in biopharmaceutical bioreactors. Computers & Chemical Engineering. 2017; 97:271–82. https://doi.org/10.1016/j.compchemeng.2016.11.037 WOS:000392775000022.

88. Amrit B, Niu SX, Bogaerts P. Macroscopic modelling of overflow metabolism and model based optimization of hybridoma cell fed-batch cultures. Biochemical Engineering Journal. 2013; 70:196–209. https://doi.org/10.1016/j.bej.2012.11.005 WOS:000344298000027.

89. Gadgil M. Development of a mathematical model for animal cell culture without pH control and its application for evaluation of clone screening outcomes in shake flask culture. Journal of Chemical
90. Xing ZZ, Bishop N, Leister K, Li ZJ. Modeling Kinetics of a Large-Scale Fed-Batch CHO Cell Culture by Markov Chain Monte Carlo Method. Biotechnology Progress. 2010; 26(1):208–19. https://doi.org/10.1002/bttp.284 WOS:000274973400027. PMID: 19834967

91. Mathur D, Singh S, Mehta A, Agrawal P, Raghava GP. In silico approaches for predicting the half-life of natural and modified peptides in blood. PloS one. 2018; 13(6):e0196829. https://doi.org/10.1371/journal.pone.0196829 PMID: 29586745

92. Ramirez OT, Mutharasan R. The Role of the Plasma-Membrane Fluidity on the Shear Sensitivity of Hybridomas Grown under Hydrodynamic Stress. Biotechnology and Bioengineering. 1990; 36(9):911–20. WOS:A1990ED68600005. https://doi.org/10.1002/bit.260360906 PMID: 18597291

93. Ramirez OT, Mutharasan R. Effect of Serum on the Plasma-Membrane Fluidity of Hybridomas—an Insight into Its Shear Protective Mechanism. Biotechnology Progress. 1992; 8(1):40–50. https://doi.org/10.1021/bp00013a007 WOS:A1992HC77500007. PMID: 1367894

94. Park S, Bae W, Chung J, Baek SC. Empirical model of the pH dependence of the maximum specific nitrification rate. Process Biochemistry. 2007; 42(12):1671–6. https://doi.org/10.1016/j.procbio.2007.09.010 WOS:000252289400016.

95. Rosso L, Lobry JR, Bajard S, Flandrois JP. Convenient Model to Describe the Combined Effects of Temperature and Ph on Microbial-Growth. Applied and Environmental Microbiology. 1995; 61(2):610–6. WOS:A1995QF42800032. https://doi.org/10.1128/aem.61.2.610-616.1995 PMID: 16534932

96. Schoolfield RM, Sharpe P, Magnuson CE. Non-linear regression of biological temperature-dependent rate models based on absolute reaction-rate theory. J Theor Biol. 1981; 88(4):719–31. https://doi.org/10.1016/0022-5193(81)90246-0 PMID: 16534932

97. Xin PP, Li B, Zhang HH, Hui J. Optimization and control of the light environment for greenhouse crop production. Scientific Reports. 2019; 9. ARTN 8650 https://doi.org/10.1038/s41598-019-44980-z WOS:000471759700003. PMID: 31209246

98. Mahdinia E, Demirci A, Berenjian A. Optimization of Bacillus subtilis natto growth parameters in glycerol-based medium for vitamin K (Menaquinone-7) production in biofilm reactors. Bioprocess and Biosystems Engineering. 2018; 41(2):195–204. https://doi.org/10.1007/s00449-017-1857-0 WOS:000422926700005. PMID: 29119323

99. Martín-Calderón JL, Bustos F, Tuesta-Reina LR, Varona JM, Caballero L, Solano F. Choice of the best equation for plasma osmolality calculation: Comparison of fourteen formulae. Clin Biochem. 2015; 48(7–8):529–33. Epub 2015/03/22. https://doi.org/10.1016/j.clinbiochem.2015.03.005 PMID: 25794428.

100. Lewis CD. Industrial and business forecasting methods: a practical guide to exponential smoothing and curve fitting. London; Boston: Butterworth Scientific; 1982.

101. Goey CH. Cascading effects in bioprocessing: the impact of cell culture environment on CHO cell behaviour and host cell protein species. 2016.

102. Kim TK, Chung JY, Sung YH, Lee GM. Relationship between cell size and specific thrombopoietin productivity in Chinese hamster ovary cells during dihydrofolate reductase-mediated gene amplification. Biotechnology and Bioprocess Engineering. 2001; 6(5):332–6.

103. Evie IM, Dickson AJ, Elvin M. Metabolite Profiling of Mammalian Cell Culture Processes to Evaluate Cellular Viability. Methods Mol Biol. 2017; 1601:137–52. https://doi.org/10.1007/978-1-4939-6960-9_12 PMID: 28470524.

104. Sellick CA, Knight D, Croxford AS, Maqood AR, Stephens GM, Goodacre R, et al. Evaluation of extraction processes for intracellular metabolite profiling of mammalian cells: matching extraction approaches to cell type and metabolite targets. Metabolomics. 2010; 6(3):427–38. https://doi.org/10.1007/s11306-010-0216-9 WOS:000279698500010.

105. Nolan RP, Lee K. Dynamic model of CHO cell metabolism. Metabolic Engineering. 2011; 13(1):108–24. https://doi.org/10.1016/j.ymben.2010.09.003 WOS:000285651100012. PMID: 20933095

106. deZengotita VM, Schmelzer AE, Miller WM. Characterization of hybridoma cell responses to elevated pCO2 and osmolality: Intracellular pH, cell size, apoptosis, and metabolism. Biotechnology and Bioengineering. 2002; 77(4):369–80. https://doi.org/10.1002/bit.10176 WOS:000173538100002. PMID: 11787010

107. Lee G, Meyer X, Biscans B, Le Lann J, Yoon E. Adaptive finite difference method for the simulation of batch crystallization. Computers & Chemical Engineering. 1999; 23:S363–S6.

108. Kontoravdi C. Systematic methodology for the development of mathematical models for biological processes. Methods Mol Biol. 2013; 1073:177–90. https://doi.org/10.1007/978-1-62703-625-2_15 PMID: 23996448.
Population balance modelling captures host cell protein dynamics in CHO cell cultures

109. Cossarizza A, Chang H-D, Radbruch A, Akdis M, Andrá I, Annunziato F, et al. Guidelines for the use of flow cytometry and cell sorting in immunological studies*. European Journal of Immunology. 2017; 47(10):1584–797. https://doi.org/10.1002/eji.201646632 PMID: 29023707

110. Munzer DGG, Ivarsson M, Usaku C, Habicher T, Soos M, Morbidelli M, et al. An unstructured model of metabolic and temperature dependent cell cycle arrest in hybridoma and fed-batch cultures. Biochemical Engineering Journal. 2015; 93:260–73. WOS:000347362100032

111. Klein T, Heinzel N, Kroll P, Brunner M, Herwig C, Neutsch L. Quantification of cell lysis during CHO bioprocesses: Impact on cell count, growth kinetics and productivity. Journal of Biotechnology. 2015; 207:67–76. WOS:000365645000013. https://doi.org/10.1016/j.jbiotec.2015.04.021 PMID: 25956245

112. Cho MH, Niles A, Huang RL, Inglese J, Austin CP, Riss T, et al. A bioluminescent cytotoxicity assay for assessment of membrane integrity using a proteolytic biomarker. Toxicology in Vitro. 2008; 22 (4):1099–106. https://doi.org/10.1016/j.tiv.2008.02.013 WOS:000256076900034. PMID: 19400464

113. Chakrabarti S, Barrow CJ, Kanwar RK, Kanwar JR. Studies to Prevent Degradation of Metabolic and Necrotic Cell Death in Primary Hepatocyte Cultures. Methods Mol Biol. 2015; 1250:349–61. https://doi.org/10.1007/978-1-4939-2074-7_27 PMID: 26272157; PubMed Central PMCID: PMC4579552.

114. Kumar S, McGinnis JF, Devellis J. Catecholamine Regulation of Lactate-Dehydrogenase in Rat-Brain Cell-Culture—Norepinephrine Differentially Increases the Rate of Synthesis of the Individual Subunits in the C6 Gial Tumor-Cell Line. Journal of Biological Chemistry. 1980; 255(6):2315–21. WOS: A1980JL71700019. PMID: 7358772

115. Cho MH, Niles A, Huang RL, Inglesie J, Austin CP, Riss T, et al. A bioluminescent cytotoxicity assay for assessment of membrane integrity using a proteolytic biomarker. Toxicology in Vitro. 2008; 22 (4):1099–106. https://doi.org/10.1016/j.tiv.2008.02.013 WOS:000256076900034. PMID: 19400464

116. Menyhart O, Harami-Papp H, Sukumar S, Schafer R, Magnani L, de Barrios O, et al. Guidelines for the selection of functional assays to evaluate the hallmarks of cancer. Biochimica Et Biophysica Acta-Reviews on Cancer. 2016; 1866(2):300–19. https://doi.org/10.1016/j.bbcan.2016.10.002 WOS:000390623900014. PMID: 27742530

117. Maes M, Vanhaecke T, Cogliati B, Yanguas SC, Willebrords J, Rogiers V, et al. Measurement of Apoptotic and Necrotic Cell Death in Primary Hepatocyte Cultures. Methods Mol Biol. 2015; 1250:349–61. https://doi.org/10.1007/978-1-4939-2074-7_27 PMID: 26272157; PubMed Central PMCID: PMC4579552.

118. Valente KN, Levy NE, Lee KH, Lenhoff AM. Applications of proteomic methods for CHO host cell protein characterization in biopharmaceutical manufacturing. Current opinion in biotechnology. 2018; 53:144–50. https://doi.org/10.1016/j.copbio.2018.01.004 PMID: 29414072

119. Park JH, Jin JH, Ji LJ, An HJ, Kim JW, Lee GM. Proteomic analysis of host cell protein dynamics in the supernatant of Fc-fusion protein-producing CHO DG44 and DUKX-B11 cell lines in batch and fed-batch cultures. Biochemistry and bioengineering. 2017; 114(10):2267–78. https://doi.org/10.1002/bit.26360 PMID: 28627725

120. Cheung MC, LaCroix R, McKenna BK, Liu L, Winkelman J, Ehrlich DJ. Intraacellular protein and nucleic acid measured in eight cell types using deep-ultraviolet mass mapping. Cytometry Part A. 2013; 83a (6):540–51. https://doi.org/10.1002/cyto.a.22277 WOS:000319348900007. PMID: 23504822

121. Kol S, Ley D, Wulf T, Decker M, Arndt R, Gutierrez JM, et al. Multiplex secertome engineering enhances recombinant protein production and purity. bioRxiv. 2019: 647214. https://doi.org/10.1101/647214

122. Chaudhuri S, Maurya P, Kaur M, Borth N, Bhatnagar S, et al. Investigation of CHO Secretome: Potential Way to Improve Recombinant Protein Production from Bioprocess. Journal of Bioprocessing & Biotechniques. 2015.

123. Chen WX, Smeekens JM, Wu RH. Systematic study of the dynamics and half-lives of newly synthesized proteins in human cells. Chemical Science. 2016; 7(2):1393–400. https://doi.org/10.1039/c5sc03826w WOS:000368835000069. PMID: 29910897

124. Bachmair A, Finley D, Varshavsky A. Invivo Half-Life of a Protein Is a Function of Its Amino-Terminal Residue. Science. 1986; 234(4773):179–86. https://doi.org/10.1126/science.3018930 WOS: A1986E225800025. PMID: 3018930

125. Jin M, Szapiel N, Zhang J, Hickey J, Ghose S. Profiling of Host Cell Proteins by Two-Dimensional Difference Gel Electrophoresis (2D-DIGE): Implications for Downstream Process Development. Biotechnology and Bioengineering. 2010; 105(2):306–16. https://doi.org/10.1002/bit.22532 WOS:000273715500009. PMID: 19739084
126. Kappatou CD, Mhamdi A, Campano AQ, Mantalaris A, Mitsos A. Model-Based Dynamic Optimization of Monoclonal Antibodies Production in Semibatch Operation—Use of Reformulation Techniques. Industrial & Engineering Chemistry Research. 2018; 57(30):9915–24. https://doi.org/10.1021/acs.iecr.7b05357 WOS:000440876800016.

127. Savizi ISP, Soudi T, Shojaosadati SA. Systems biology approach in the formulation of chemically defined media for recombinant protein overproduction. Appl Microbiol Biotechnol. 2019; 103 (20):8315–26. https://doi.org/10.1007/s00253-019-10048-1 PMID: 31418052.

128. Spens E, Haggstrom L. Defined protein and animal component-free NS0 fed-batch culture. Biotechnol Bioeng. 2007; 98(6):1183–94. https://doi.org/10.1002/bit.21509 PMID: 17516495.

129. Xie LZ, Wang DIC. Applications of Improved Stoichiometric Model in Medium Design and Fed-Batch Cultivation of Animal-Cells in Bioreactor. Cytotechnology. 1994; 15(1–3):17–29. https://doi.org/10.1007/BF00762376 WOS:A1994QC63400004. PMID: 7765929

130. Seo JS, Kim YJ, Cho JM, Baek E, Lee GM. Effect of culture pH on recombinant antibody production by a new human cell line, F2N78, grown in suspension at 33.0 A degrees C and 37.0 A degrees C. Applied Microbiology and Biotechnology. 2013; 97(12):5283–91. https://doi.org/10.1007/s00253-013-4849-2 WOS:000319609400009. PMID: 23553031

131. Masterton RJ, Smales CM. The impact of process temperature on mammalian cell lines and the implications for the production of recombinant proteins in CHO cells. Pharmaceutical bioprocessing. 2014; 2(1):49–61.